- Volumes 84-95 (2024)
-
Volumes 72-83 (2023)
-
Volume 83
Pages 1-258 (December 2023)
-
Volume 82
Pages 1-204 (November 2023)
-
Volume 81
Pages 1-188 (October 2023)
-
Volume 80
Pages 1-202 (September 2023)
-
Volume 79
Pages 1-172 (August 2023)
-
Volume 78
Pages 1-146 (July 2023)
-
Volume 77
Pages 1-152 (June 2023)
-
Volume 76
Pages 1-176 (May 2023)
-
Volume 75
Pages 1-228 (April 2023)
-
Volume 74
Pages 1-200 (March 2023)
-
Volume 73
Pages 1-138 (February 2023)
-
Volume 72
Pages 1-144 (January 2023)
-
Volume 83
-
Volumes 60-71 (2022)
-
Volume 71
Pages 1-108 (December 2022)
-
Volume 70
Pages 1-106 (November 2022)
-
Volume 69
Pages 1-122 (October 2022)
-
Volume 68
Pages 1-124 (September 2022)
-
Volume 67
Pages 1-102 (August 2022)
-
Volume 66
Pages 1-112 (July 2022)
-
Volume 65
Pages 1-138 (June 2022)
-
Volume 64
Pages 1-186 (May 2022)
-
Volume 63
Pages 1-124 (April 2022)
-
Volume 62
Pages 1-104 (March 2022)
-
Volume 61
Pages 1-120 (February 2022)
-
Volume 60
Pages 1-124 (January 2022)
-
Volume 71
- Volumes 54-59 (2021)
- Volumes 48-53 (2020)
- Volumes 42-47 (2019)
- Volumes 36-41 (2018)
- Volumes 30-35 (2017)
- Volumes 24-29 (2016)
- Volumes 18-23 (2015)
- Volumes 12-17 (2014)
- Volume 11 (2013)
- Volume 10 (2012)
- Volume 9 (2011)
- Volume 8 (2010)
- Volume 7 (2009)
- Volume 6 (2008)
- Volume 5 (2007)
- Volume 4 (2006)
- Volume 3 (2005)
- Volume 2 (2004)
- Volume 1 (2003)
• Preparation of multiunit colon-targeted granules using plasticizer dry powder coating technology.
• In vivo imaging for assessing the targeting of plasticizer dry powder-coated granules.
• Improving the therapeutic effect of baicalin on ulcerative colitis in rats.
Baicalin (BA) is a flavonoid extracted from the dried root of Scutellaria baicalensis Georgi with excellent antioxidant and anti-inflammatory biological activities. In this study, Eudragit S100 was used as the colonic target material to prepare BA colonic targeting granules (EBCGs) based on plasticizer dry powder coating technology to improve the targeting transportation performance of BA. In vitro studies showed that EBCGs with pH-sensitive properties were successfully prepared by plasticizer dry powder coating, and in vivo animal imaging studies showed that EBCGs could deliver BA to the colon and inhibit the release of BA in the upper gastrointestinal tract (GIT). In vivo studies showed that EBCGs had good therapeutic effects in colitis, which reduced expression levels of tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) and increased superoxide dismutase (SOD) activities in the colonic tissues of rats with colitis. In conclusion, Eudragit S100 could be used for the preparation of multi-unit oral colon-targeted formulations by plasticizer dry powder coating technology, and our prepared EBCGs had good colon-targeting properties, which could improve the therapeutic effect and provide a potential application for ulcerative colitis (UC).